- Home
- SILA vs GYRE Comparison
SILA vs GYRE Comparison
Compare SILA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILA
- GYRE
- Stock Information
- Founded
- SILA 2013
- GYRE 2002
- Country
- SILA United States
- GYRE United States
- Employees
- SILA N/A
- GYRE N/A
- Industry
- SILA
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SILA
- GYRE Health Care
- Exchange
- SILA NYSE
- GYRE Nasdaq
- Market Cap
- SILA 1.2B
- GYRE 1.3B
- IPO Year
- SILA N/A
- GYRE N/A
- Fundamental
- Price
- SILA $24.42
- GYRE $13.12
- Analyst Decision
- SILA Strong Buy
- GYRE
- Analyst Count
- SILA 3
- GYRE 0
- Target Price
- SILA $29.00
- GYRE N/A
- AVG Volume (30 Days)
- SILA 450.8K
- GYRE 53.3K
- Earning Date
- SILA 11-12-2024
- GYRE 11-13-2024
- Dividend Yield
- SILA 6.54%
- GYRE N/A
- EPS Growth
- SILA N/A
- GYRE N/A
- EPS
- SILA 0.37
- GYRE N/A
- Revenue
- SILA $186,225,000.00
- GYRE $105,033,000.00
- Revenue This Year
- SILA N/A
- GYRE $25.32
- Revenue Next Year
- SILA N/A
- GYRE $12.95
- P/E Ratio
- SILA $66.09
- GYRE N/A
- Revenue Growth
- SILA N/A
- GYRE N/A
- 52 Week Low
- SILA $20.20
- GYRE $8.26
- 52 Week High
- SILA $26.50
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- SILA N/A
- GYRE 41.11
- Support Level
- SILA N/A
- GYRE $13.07
- Resistance Level
- SILA N/A
- GYRE $19.00
- Average True Range (ATR)
- SILA 0.00
- GYRE 1.16
- MACD
- SILA 0.00
- GYRE -0.21
- Stochastic Oscillator
- SILA 0.00
- GYRE 7.39
About SILA SILA REALTY TRUST INC
Sila Realty Trust Inc is a real estate investment trust. Its investment objective is to pay regular cash distributions to stockholders and to preserve, protect, and return capital contributions to stockholders. The company owns and manages healthcare assets. The company generates revenue from real estate investments in healthcare properties.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.